azd5069
Small moleculeexperimental
Clinical trial activity
15 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT00953888)
Timeline
Indications
Studied for
- Agammaglobulinemia · Phase 1
- Antimetabolites · Phase 1
- Asthma · Phase 2
- Bronchiectasis · Phase 2
- Bronchitis · Phase 2
- Drugs, Investigational · Phase 1
- Healthy Volunteers · Phase 1
- Lung Diseases · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Pharmacokinetics · Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
Mechanism of action
- Interleukin-8 receptor BANTAGONIST
CXCR2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd5069
- azd5069
- n-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02583477 | Phase 1/Phase 2 (Phase 2) | Mar 25, 2016 | AstraZeneca, University of Glasgow |
| NCT02499328 | Phase 1/Phase 2 (Phase 2) | Aug 5, 2015 | AstraZeneca, MedImmune, University of Texas at Houston |
| NCT01890148 | Phase 1 | Mar 1, 2014 | AstraZeneca, Lung Clinic Grosshansdorf Germany |
| NCT01989520 | Phase 1 | Jan 1, 2014 | AstraZeneca, IQVIA |
| NCT01962935 | Phase 1 | Nov 1, 2013 | AstraZeneca, IQVIA |
| NCT01735240 | Phase 1 | Dec 1, 2012 | AstraZeneca, IQVIA |
| NCT01704495 | Phase 2 | Nov 1, 2012 | AstraZeneca |
| NCT01480739 | Phase 1 | Dec 1, 2011 | AstraZeneca, IQVIA |
| NCT01332903 | Phase 1 | May 1, 2011 | AstraZeneca, IQVIA |
| NCT01255592 | Phase 2 | Feb 1, 2011 | AstraZeneca |
| NCT01233232 | Phase 2 | Nov 1, 2010 | AstraZeneca |
| NCT01100047 | Phase 1 | May 1, 2010 | AstraZeneca, Richmond Pharmacology |
| NCT01083238 | Phase 1 | Feb 1, 2010 | AstraZeneca, IQVIA |
| NCT01051505 | Phase 1 | Jan 1, 2010 | AstraZeneca, IQVIA |
| NCT00953888 | Phase 1 | Jul 1, 2009 | AstraZeneca |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 15 | 15 | 2 | 2009 |
| IQVIA | For profit | 7 | 0 | 1 | 2010 |
| Lung Clinic Grosshansdorf Germany | Academic/Hospital | 1 | 0 | 1 | 2014 |
| MedImmune | For profit | 1 | 0 | 1 | 2015 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2010 |
| University of Glasgow | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2015 |
7 organizations
Page 1 / 1